Nitresan (Nitrendipine)

Nitrendipine blocks L‑type calcium channels located on vascular smooth‑muscle cells. By inhibiting calcium entry, it prevents muscle contraction, causing the blood vessels to relax and dilate. This vasodilation lowers peripheral vascular resistance, which in turn reduces systemic arterial pressure.

The exact dose of Nitresan is individualized by the prescribing healthcare professional based on the patient’s blood‑pressure profile, age, renal and hepatic function, and concomitant medications. The prescriber determines the appropriate starting dose and any necessary titration.

Limited clinical data are available on the use of nitrendipine in pregnancy, and it is generally advised to avoid it unless the potential benefit outweighs the risk to the fetus. Likewise, because it is excreted in breast milk, caution is recommended for nursing mothers, and alternative therapies are often preferred.

To place an order, submit an enquiry on the Nitresan product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and assistance with import documentation.

Both nitrendipine (Nitresan) and amlodipine belong to the dihydropyridine calcium‑channel blocker family and lower blood pressure by vasodilation. Nitrendipine typically has a shorter half‑life and may require once‑daily dosing, whereas amlodipine has a longer duration of action, often allowing for flexible dosing intervals. Choice between them depends on patient response, tolerability, and physician preference.

Nitresan tablets should be stored at temperatures below 25 °C, in their original packaging, and protected from moisture and direct sunlight. Do not store in bathrooms or other humid environments, and keep out of reach of children.

Nitresan is taken orally, usually with a glass of water. It can be taken with or without food, but consistent administration with respect to meals helps maintain stable drug levels. Patients should follow the dosing schedule prescribed by their healthcare provider.

The most serious adverse events include severe hypotension, which can cause fainting or shock, myocardial infarction in susceptible individuals, and rare cases of hepatic dysfunction or severe allergic reactions such as anaphylaxis. Patients should seek immediate medical attention if they experience symptoms like chest pain, sudden weakness, or signs of an allergic reaction.

Nitresan is contraindicated in patients with known hypersensitivity to nitrendipine or any other dihydropyridine calcium‑channel blockers. It should also be avoided in individuals with severe aortic stenosis, uncontrolled heart failure, or those taking strong CYP3A4 inhibitors that could markedly increase drug concentrations.